Morgan Stanley Cure Vac N.V. Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
A detailed history of Morgan Stanley transactions in Cure Vac N.V. stock. As of the latest transaction made, Morgan Stanley holds 145,681 shares of CVAC stock, worth $387,511. This represents 0.0% of its overall portfolio holdings.
Number of Shares
145,681
Previous 307,905
52.69%
Holding current value
$387,511
Previous $1.05 Million
59.08%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding CVAC
# of Institutions
92Shares Held
12.3MCall Options Held
164KPut Options Held
117K-
Israel Englander Millennium Management LLC | New York, Ny2.42MShares$6.43 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.25MShares$6 Million0.0% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.57MShares$4.17 Million10.6% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.01MShares$2.69 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct780KShares$2.07 Million0.01% of portfolio
About CureVac N.V.
- Ticker CVAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,467,008
- Market Cap $499M
- Description
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...